发布求助
文献互助 智能选刊 最新文献

Drugs of The Future最新文献

筛选
英文 中文
Freshwater ascomycetes from southern Australia: Melanascomaceae fam. nov., Melanascoma panesporagen. et. sp. nov., and Pleurotheciumbruniussp. nov. 澳大利亚南部的淡水子囊菌：Melanascomaceae fam.
4区 医学
Drugs of The Future Pub Date : 2023-06-01 Epub Date: 2023-05-25 DOI: 10.3114/fuse.2023.11.07
S C Fryar, D E A Catcheside
{"title":"Freshwater ascomycetes from southern Australia<i>: Melanascomaceae fam. nov., Melanascoma panespora</i><i>gen. et. sp. nov.,</i> and <i>Pleurothecium</i><i>brunius</i><i>sp. nov</i>.","authors":"S C Fryar, D E A Catcheside","doi":"10.3114/fuse.2023.11.07","DOIUrl":"10.3114/fuse.2023.11.07","url":null,"abstract":"<p><p>During a survey of freshwater fungi in temperate southern Australia, two new taxa were found, <i>Melanascoma panespora</i> and <i>Pleurothecium</i> <i>brunius</i>. Morphological and molecular data place <i>Melanascoma panespora</i> in the <i>Diaporthomycetidae</i> representing a new genus. <i>Melanascoma</i>, along with <i>Proliferophorum</i> and <i>Paraproliferophorum</i>, form a new lineage and the family <i>Melanascomaceae</i> is introduced. Phylogenetic analyses using ITS, 28S, and 18S nrRNA gene sequences,, along with morphological examination revealed <i>Pleurothecium brunius</i> to be a new species of <i>Pleurothecium</i>, sister to <i>P. aquaticum</i>. <b>Citation:</b> Fryar SC, Catcheside DEA (2023). Freshwater ascomycetes from southern Australia<i>: Melanascomaceae fam. nov., Melanascoma panespora</i> <i>gen. et. sp. nov.,</i> and <i>Pleurothecium</i> <i>brunius</i> <i>sp. nov</i>. <i>Fungal Systematics and Evolution</i> <b>11</b>: 85-93. doi: 10.3114/fuse.2023.11.07.</p>","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"21 1","pages":"85-93"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88686751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Liver Meeting 2022 - American Association for the Study of Liver Diseases (AASLD). 73rd Annual Meeting. Washington, D.C. - November 4-8, 2022 2022年肝脏会议-美国肝病研究协会(AASLD)。第73届年会。华盛顿特区——2022年11月4日至8日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.2.3521855
J. Gavazzi
{"title":"The Liver Meeting 2022 - American Association for the Study of Liver Diseases (AASLD). 73rd Annual Meeting. Washington, D.C. - November 4-8, 2022","authors":"J. Gavazzi","doi":"10.1358/dof.2023.48.2.3521855","DOIUrl":"https://doi.org/10.1358/dof.2023.48.2.3521855","url":null,"abstract":"The Liver Meeting-the American Association for the Study of Liver Diseases (AASLD) 2022 annual meeting-returned to in-person attendance for the first time in 2 years since the COVID-19 public health emergency began and included a virtual option. Comprised of scientists and healthcare profession-als, AASLD is the leading organization committed to preventing and curing liver disease. The \"hottest meeting in hepatology, \" according to the AASLD, included plenary sessions, presenta-tions and over 4,800 scientific s highlighting the latest scientific advancements in the field of hepatology. Research and clinical trial updates were provided in many specific liver disease areas, including hepatitis, fibrosis, nonalcoholic fatty liver disease, cirrhosis, nonalcoholic steatohepatitis, trans-plantation, and so on. Along with groundbreaking research in hepatology, many presentations included the impact of COVID-19 on patients with these diseases. This report highlights a selec-tion of presentations about treatment updates provided during the conference.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tinlarebant. Retinol-binding protein 4 (RBP4) inhibitor, Treatment of Stargardt disease, Treatment of dry age-related macular degeneration Tinlarebant。视黄醇结合蛋白4 (RBP4)抑制剂，治疗Stargardt病，治疗干性老年性黄斑变性
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.3.3474539
S. Vaccaro, L. Ferro Desideri, P. Bianchi, A. Vagge, R. Manocchio, V. Scorcia, C. Traverso, F. Calabria, G. Giannaccare
{"title":"Tinlarebant. Retinol-binding protein 4 (RBP4) inhibitor, Treatment of Stargardt disease, Treatment of dry age-related macular degeneration","authors":"S. Vaccaro, L. Ferro Desideri, P. Bianchi, A. Vagge, R. Manocchio, V. Scorcia, C. Traverso, F. Calabria, G. Giannaccare","doi":"10.1358/dof.2023.48.3.3474539","DOIUrl":"https://doi.org/10.1358/dof.2023.48.3.3474539","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"34 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imlunestrant. Selective estrogen receptor degrader (SERD), Treatment of breast cancer Imlunestrant。选择性雌激素受体降解剂(SERD)，治疗乳腺癌
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.1.3476558
{"title":"Imlunestrant. Selective estrogen receptor degrader (SERD), Treatment of breast cancer","authors":"","doi":"10.1358/dof.2023.48.1.3476558","DOIUrl":"https://doi.org/10.1358/dof.2023.48.1.3476558","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66445938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease Tozorakimab。抗il -33单克隆抗体，慢性阻塞性肺病和哮喘的治疗，特应性皮炎的治疗，糖尿病肾病的治疗
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.2.3474010
M. Cazzola, P. Rogliani, L. Calzetta, M. Matera
{"title":"Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease","authors":"M. Cazzola, P. Rogliani, L. Calzetta, M. Matera","doi":"10.1358/dof.2023.48.2.3474010","DOIUrl":"https://doi.org/10.1358/dof.2023.48.2.3474010","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 2022 药物化学和使能技术的最新趋势。来自医学研究学会会议的亮点。伦敦——2022年12月8日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.3.3567668
P. Brown, A. Merritt, S. Skerratt, M. Swarbrick
{"title":"Recent trends in medicinal chemistry and enabling technologies. Highlights from the Society for Medicines Research Conference. London - December 8, 2022","authors":"P. Brown, A. Merritt, S. Skerratt, M. Swarbrick","doi":"10.1358/dof.2023.48.3.3567668","DOIUrl":"https://doi.org/10.1358/dof.2023.48.3.3567668","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
NCX-470. Nitric oxide-donating prostaglandin analogue, Treatment of glaucoma, Treatment of ocular hypertension ncx - 470。一氧化氮供体前列腺素类似物，治疗青光眼，治疗高眼压
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.1.3448337
{"title":"NCX-470. Nitric oxide-donating prostaglandin analogue, Treatment of glaucoma, Treatment of ocular hypertension","authors":"","doi":"10.1358/dof.2023.48.1.3448337","DOIUrl":"https://doi.org/10.1358/dof.2023.48.1.3448337","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity Tirzepatide。双GLP-1/GIP受体激动剂，治疗2型糖尿病和肥胖症
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.3.3521861
T. L. Jensen, A. Brønden, K. Karstoft, D. Sonne, M. B. Christensen
{"title":"Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity","authors":"T. L. Jensen, A. Brønden, K. Karstoft, D. Sonne, M. B. Christensen","doi":"10.1358/dof.2023.48.3.3521861","DOIUrl":"https://doi.org/10.1358/dof.2023.48.3.3521861","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66447024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pruxelutamide. Androgen receptor antagonist, Treatment of metastatic castration-resistant prostate cancer, Treatment of metastatic breast cancer Pruxelutamide。雄激素受体拮抗剂，治疗转移性去势抵抗性前列腺癌，治疗转移性乳腺癌
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.1.3435133
{"title":"Pruxelutamide. Androgen receptor antagonist, Treatment of metastatic castration-resistant prostate cancer, Treatment of metastatic breast cancer","authors":"","doi":"10.1358/dof.2023.48.1.3435133","DOIUrl":"https://doi.org/10.1358/dof.2023.48.1.3435133","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Heart Association (AHA) Scientific Sessions - 2022 Annual Meeting. Chicago/Virtual - November 5-7, 2022 美国心脏协会(AHA)科学会议- 2022年年会。芝加哥/Virtual - 2022年11月5日至7日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2023-01-01 DOI: 10.1358/dof.2023.48.2.3521848
D. Soundararajan
{"title":"American Heart Association (AHA) Scientific Sessions - 2022 Annual Meeting. Chicago/Virtual - November 5-7, 2022","authors":"D. Soundararajan","doi":"10.1358/dof.2023.48.2.3521848","DOIUrl":"https://doi.org/10.1358/dof.2023.48.2.3521848","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信